Clinical Trials Logo

HTN clinical trials

View clinical trials related to HTN.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06259175 Not yet recruiting - Clinical trials for Arterial Hypertension

Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)

TRIPTYCH
Start date: May 1, 2024
Phase:
Study type: Observational

This is a multi-centre, observational, ambispective study, which will retrospectively and prospectively collect clinical and socio-demographic data from medical records of outpatients with arterial hypertension (HTN) initiated with the amlodipine/indapamide/perindopril SPC in real clinical settings. 375 patients to be included in the study in order for at least 300 patients to complete the study and provide an estimated 90% power of the study. 75 outpatient general practitioners and cardiologists will participate in this study.

NCT ID: NCT05850416 Not yet recruiting - HTN Clinical Trials

mGlide-Care: A Partnership With Caregivers

Start date: January 2025
Phase: N/A
Study type: Interventional

Hypertension (HTN) is the most significant stroke, cardiovascular disease and dementia risk factor and is substantially under-treated especially in older persons. In this study the investigators will develop mGlide-Care to address uncontrolled HTN in people with mild cognitive impairment (MCI) and early stage Alzheimer's Disease and Alzheimer's Disease Related Dementia (AD/ADRD). mGlide-Care is adapted from mGlide which is a mHealth (mobile health technology) mediated care model for HTN care. Aim 1 will engage stakeholders to study the acceptability of mHealth mediated HTN care and will use their input to develop mGlide-Care. Stakeholders are persons with early stage AD/ADRD and MCI, unpaid family caregivers, primary care providers, geriatricians and clinical pharmacists. Aim 2 is a feasibility pilot to test mGlide-Care vs. usual care in 75 participants with uncontrolled HTN and early stage AD/ADRD or MCI. Caregivers will assist participants. Outcomes will include HTN control and participant and caregiver reported measures.